IL6 and type 2 diabetes mellitus: Recent studies demonstrated that empagliflozin and DAPA reduce cardiac interstitial macrophage infiltration in prediabetic rats and in infarcted rat hearts, decrease mRNA expressions of interleukin-1β (IL-1β), interleukin-6 (IL-6) and mitigate the activation of Nlrp3/ASC inflammasome, thus attenuate the development of DCM in T2DM mouse model [14–16].